Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1983 Dec;2(6):541-7.
doi: 10.1007/BF02016562.

Susceptibility of gram-negative bacteria and Staphylococcus aureus to combinations of ticarcillin and clavulanic acid

Susceptibility of gram-negative bacteria and Staphylococcus aureus to combinations of ticarcillin and clavulanic acid

P Casey et al. Eur J Clin Microbiol. 1983 Dec.

Abstract

Four hundred and fifty-nine blood culture isolates were tested for susceptibility to ticarcillin alone and ticarcillin plus clavulanic acid, a potent beta-lactamase inhibitor. The susceptibilities of the Staphylococcus aureus strains to cloxacillin, methicillin, vancomycin, rifampicin, cefoperazone, ceftriaxone and moxalactam and of the gram-negative strains to Augmentin, azlocillin, mezlocillin, piperacillin, cefoperazone, ceftriaxone, cefotaxime, cefsulodin and tobramycin were also measured. Seventy-one percent of staphylococcal strains were beta-lactamase positive. In the presence of clavulanic acid the ticarcillin spectrum was extended to include beta-lactamase producing Staphylococcus aureus, Serratia marcescens and Klebsiella. All the ticarcillin-resistant Enterobacteriaceae were rendered ticarcillin-sensitive by clavulanic acid. The anti-Pseudomonas activity of ticarcillin plus clavulanic acid differed little from that of azlocillin and piperacillin and was comparable to that of the third generation cephalosporins. The combination of ticarcillin with clavulanic acid should be tested in the treatment of patients with infections caused by ticarcillin-sensitive and ticarcillin-resistant bacteria.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Lancet. 1978 Jul 29;2(8083):257 - PubMed
    1. Drugs. 1980 Nov;20(5):325-52 - PubMed
    1. J Antimicrob Chemother. 1981 Mar;7(3):229-36 - PubMed
    1. J Antimicrob Chemother. 1981 Apr;7(4):441-4 - PubMed
    1. Antimicrob Agents Chemother. 1978 Jun;13(6):930-8 - PubMed

MeSH terms